{"analyses":[{"ciLowerLimit":"0.773","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.169","estimateComment":"Cox regression model with treatment as the independent variable, stratified by randomization strata","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.628","paramType":"Hazard Ratio (HR)","paramValue":"0.951","statisticalComment":"Stratified by randomization strata","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.7","upperLimit":"15.0","value":"14.4"},{"groupId":"OG001","lowerLimit":"11.7","upperLimit":"15.6","value":"14.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"341"}],"units":"Participants"}],"description":"Measured by imaging studies; confirmed by independent imaging review","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects randomized to receive placebo. Approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. Three complete doses were given at approximately 2 week intervals.","id":"OG000","title":"APC-Placebo"},{"description":"All subjects randomized to receive sipuleucel-T. Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consists of 3 doses administered approximately 2 weeks apart.","id":"OG001","title":"Sipuleucel-T"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Analysis conducted at the time of overall survival analysis","title":"Time to Objective Disease Progression","type":"SECONDARY","unitOfMeasure":"Weeks"}